For many biopharma leaders, staying competitive means reevaluating their current QC microbiology lab environments – and reimagining what an ideal, future-ready lab should look like.
In the last decade, a growing number of the world’s leading biopharmaceutical manufacturers have embraced more proactive, forward-thinking approaches that include digitization and automation in their QC Micro labs. Case studies have shown that digital and automated technologies deliver 30% to 40% increases in productivity and could lead to over 50% reduction in overall quality-control costs.
Automating a QC micro lab can also ensure data integrity and compliance by reducing manual errors and variability. Use cases have demonstrated that automation can result in a more than 65% reduction in deviations and can help prevent major compliance issues. This continues to be critical, because the cost of a single FDA action can include hundreds of hours of work.
Obviously, biopharmaceutical leaders have more than their fair share of challenges to manage. Even though they are pulled in many different directions, the most effective leaders will occasionally pause to take a broader view of the total QC lab environment and the ways in which their labs may be under-performing. Doing this well can lead to innovative solutions that result in a higher performing QC micro lab and a more empowered team.
To support your own lab performance analysis, let’s look at three areas that should be priorities when creating an optimized lab environment.
There is constant pressure to increase the speed of manufacturing without sacrificing quality. However, many QC micro labs continue to run manual tests in sequence that can take anywhere from 5 to 14 days. Manual testing also increases the chance of human error, making it difficult to achieve maximum quality and efficiency. The COVID-19 pandemic has recently underscored the importance of speed and digitization and finally convinced many drug and vaccine manufacturers that the time for digitization of manual processes is now.
How can you improve your lab’s speed? Employing digitization and rapid detection for some or all QC Micro processes can have an immediate impact on the speed of manufacturing. Solutions such as the Growth Direct® System can automate the entire process and cut the time needed to complete a test by half, saving time and eliminating the risks of human error. Looking ahead, quality control measures that monitor workflows and detect microbial contamination will continue to be mission-critical, particularly in enabling increased speed and capacity.
The scale of manufacturing is also radically changing, with commercial manufacturing of some therapeutics and vaccines measured not in millions of doses, but in billions. Companies will have to scale up their manufacturing as well as their QC testing to support this level of manufacturing. Post-pandemic, the drug and vaccine manufacturers that have successfully expanded their scale in safe and effective ways have a clear advantage in the marketplace, while being better prepared for the next pandemic.
Up to 659 cassettes bearing microbiological samples can be loaded into the Growth Direct® System for high-volume testing.
Automating slow, error-prone, manual QC processes allows manufacturers to confidently accelerate their bioprocessing, maximize capacity, and reduce operational risk and downtime – all while maintaining the highest standards of data integrity. Technologies such as the Growth Direct® System can help modernize QC Micro and enable teams to meet regulators expectations, sustain competitive advantage, and, ultimately, serve patient needs and safety.
Biopharmaceutical manufacturing includes newer treatments like cell and gene therapies, in addition to monoclonal antibodies, vaccines, and tissue and blood products. The processes for these complex therapeutics demand new standards for automation, sterility, speed, and quality. Unfortunately, traditional microbial QC test methods fall short due to several drawbacks:
These shortcomings can slow shipments of life-saving therapeutics when they're needed most. In addition, data integrity issues can have potentially negative effects – not only on patients, but on a manufacturer’s bottom line and corporate reputation. Consequently, makers of novel complex therapies have been among the most willing adopters of high-capacity, rapid automation platforms such as the Growth Direct® System.
How can rapid automation help your lab expand its scope? In addition to minimizing necessary test steps for faster results, think about advanced data and reporting capabilities and seamless integration with a wide range of laboratory information management systems (LIMS). These could be the cornerstones of a paperless solution robust enough to support your needs for risk mitigation, regulatory compliance, and increased patient safety.
Digitalization and automation of the QC Micro lab are critical to the future of biopharma manufacturing, increasing speed and capacity even as they help elevate the level of attention paid to patient safety. To face that future with confidence, we invite you to contact Rapid Micro Biosystems. Or you can ask for a virtual or in-person demonstration of the Growth Direct® System today.